Johnson & Johnson (JNJ)

FairStock Score: 62/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I see Johnson & Johnson as a durable healthcare franchise operating in Innovative Medicine and MedTech, with 138,200 employees and a low beta of 0.23. The record is not smooth. Revenue was $85.2B in fiscal 2023, $88.8B in fiscal 2024, and $94.2B in fiscal 2025, while net income moved from $35.2B in fiscal 2023 to $14.1B in fiscal 2024 and $26.8B in fiscal 2025. FairStock labels it a STALWART, citing 12.7% annual profit growth over five years and 2.7% revenue growth. Its moat rests on a broad medicine and device portfolio and global scale, but the filed numbers are uneven. In fiscal Q3 2026, the quarter ended 2026-09-27, revenue was $25.4B, yet net income was only $210M and diluted EPS was $0.09; in fiscal Q2 2026, the quarter ended 2026-06-28, net income was $5.5B and diluted EPS $2.27. That swing demands explanation.

In plain English: Johnson & Johnson makes medicines and medical devices and sells them around the world. The business looks financially strong, with solid cash generation and a low debt load, but the latest reported quarter showed a big drop in profit that needs watching. At the recent price, the shares look expensive compared with reported earnings and stated net assets.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-09-27) · fiscal Q2 2026 10-Q (period ended 2026-06-28) · fiscal Q1 2026 10-Q (period ended 2026-03-29) · fiscal Q3 2025 10-Q (period ended 2025-09-28) · FY2025 10-K (period ended 2025-12-28) · FY2024 10-K (period ended 2024-12-29) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer